摘要
目的：比较奥沙利铂联合多西他赛或替吉奥治疗进展期胃癌（AGC）的疗效及安全性。方法选取2011年4月—2013年1月在青海省第五人民医院住院的 AGC 患者共62例，采用随机数字表法将患者随机分为两组，A 组31例接受奥沙利铂联合替吉奥方案，B 组31例接受奥沙利铂联合多西他赛方案；比较两组反应率（RR）、疾病控制率（DCR）、疾病无进展时间、总生存时间和不良反应。结果A 组 RR、DCR、中位疾病无进展时间（mPFS）、中位生存时间（mOS）分别为48．4％、67．7％、5．4个月、9．0个月；B 组相应为54．8％、77．4％、6．2个月、9．8个月，差异均无统计学意义（χ^2＝0．26，P ＝0．711；χ^2＝0．73，P ＝0．393；χ^2＝0．51，P ＝0．473；χ^2＝0．03，P ＝0．829）。A 组Ⅰ～Ⅱ级外周神经毒性（9．7％∶22．6％）及恶心呕吐发生率（12．9％∶32．3％）均低于 B 组（χ^2＝5．78，P ＝0．002；χ^2＝4．63，P ＝0．016）。结论两种化疗方案治疗 AGC 的疗效相当，奥沙利铂联合替吉奥方案可作为进展期胃癌的一种化疗方案，且在耐受性方面优于奥沙利铂联合多西他赛方案。
Objective To evaluate the efficacy and safety of combination therapy of oxaliplatin and S-1 vs oxaliplatin and docetaxel for advanced gastric cancer （AGC）patients.Methods From April 201 1 to January 201 3,62 cases of AGC were collected in the Fifth People′s Hospital of Qinghai Province.All cases were randomly divided into group A （31 cases）and B （31 cases）by random number table.In group A,oxaliplatin plus S-1 was administered,and in group B,oxaliplatin plus docetaxel was applied.The response rate （RR）, time of diseases controlled rate （DCR）,progression-free survival （PFS）,overall survival （OS）and adverse reactions of the two groups were observed and compared.Results There were no statistically differences between group A and group B in RR （48.4% vs 54.8%）,DCR （67.7% vs 77.4%）,mPFS （5.4 months vs 6.2 months）,mOS （9.0 months vs 9.8 months）,and the statistical values were as follows：χ^2 =0.26,P =0.71 1 ;χ^2 =0.73,P =0.393;χ^2 =0.51 ,P =0.473;χ^2 =0.03,P =0.829.The incidence of degrees Ⅰ-Ⅱperipheral neuropathy （9.7% vs 22.6%）,nausea and vomiting （1 2.9% vs 32.3%）in group A were signifi-cantly lower than those in group B （χ^2 =5.78,P =0.002;χ^2 =4.63,P =0.01 6）.Conclusion Both the two chemotherapies are similar in therapeutic effect for patients with AGC.Oxaliplatin plus S-1 treatment may be better than oxaliplatin plus docetaxel in the tolerance of patients.
出处
《国际肿瘤学杂志》
CAS
2015年第6期426-429,共4页
Journal of International Oncology
